London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Just noticed this is still showing in my account presumably it'll stay there until end of FY?
Strong buy incase anybody wants mine.
Interpath, the Administrators, are selling off assets. Funds achieved are being returned to Creditors ( Oxford Finance predominantly).
Interpath were appointed by OF, so have no responsibilty towards Shareholders.
So far as I can establish, Interpath are yet to aply for a Winding Up order. The matter could therefore drag on for many months.
In short, shareholders are left with noting ( shares are worthless).
Given the Administration and De-listing of the shares it is worth establishing a Capital Loss. Best to get an Accountant's opinion as I will.
What happens to our shares now?
Who makes money from this debacle.
How long does it take to leave our portfolio's, as its dragging it down.
Well well well - what i thought was a good investment -
ALL GONE down the drain -
This business could have made millions
4d carved up and sold off. A sorry end for the company and shareholders. I’ve invested into crypto but was once heavily vested here and synairgen. People warn about unregulated exchanges in the crypto sphere but they have nothing on the risks involved with AIM. It really is a minefield. I doubt I’ll ever return to it.
Any updates around this and Shareholder Action Group etc. I deleted Telegram and hence no longer in the group
I sent email ages ago but did not get any response / invite to join AG
Much activity going on. We will not let them ever ever ever rest for this.
And I hope they read this.
Email to be part of it.
Colin the AIM market is a Bear-pit in more ways than one. Seem to recall someone saying, many months ago, Interpath were good, they bring Company's back from Administration. I for one did not believe it sadly for all of us. They are part of a system that feeds the well-heeled, the minnions are "Gun-fodder".
The Market Regulators should remember the purpose of the market, without investors, big and small, businesses will not develop especially SME's
My view on Interpath's objuracy, is to go straight for Peyton and fellow Defendant with a Statement of Intent to Claim.......(aSolicitor will know the wording to draw details of Insurers).
Otherwise Interpath will just Stonewall and drag it out too wear claimants down.
Interpath need naming and shaming.
Sharesoc are fully behind this.
Interpath have been nothing but self-serving . Taken £7.4m of our money for dogsbody work. I could , after some training, do their job at £635 an hour with no problems.They have done nothing but promote secrecy and subservience to financial greed. They reflect all that is wrong with this growing two-tier society in the UK. Institutionalised greed. While junior doctors and teachers strike-more due to overwork than pay- they fleece millions from helpless shareholders. I wouldn’t mind so much if they lived up to their marketing promo sales literature, but they don’t. I was provided with 2 English law articles by a top London solicitor and they used their own to deny it, not releasing names of insurers. This was back in July, and they have only promoted the carnage I am witness to in the SAG. Divorces, family rifts, severe depressions and breakdowns. This was not a caveat emptor case where people can say only invest what you can afford to lose! Investing is not like that in reality. These guys led us a merry dance from the beginning to the duplicitous relisting end. Sickening.
Interpath are part of the abuse.
No guarantees of anything, but nowhere near giving up. A lot of us are active. These two Shamen peddling seductive wares deserve justice.
So have Interpath notified the Insurers of Intent to Claim, without actually divulging who the Insurers are ?
Seems like Interpath need a rocket where the Sun don't shine!
Yes. Now managed by Interpath who obfuscate and over-control to a pathological degree, and even under legal request, will not release name of insurers.
Is the Insurance you are referring to Professional Indemnity Cover which DP and AS have, and or others ?
By a long chalk.
The SAG are very very active and all shareholders can be part of this.
We are in contact with the FCA( fwiw), SFO, are supported by Sharesoc and are actively seeking action.
Don’t give up quite yet.
The suffering caused by these seductive peddlers is immense and unforgiveable.
Emails not allowed so you fill in the asterisks.
Give holding and sum invested.
You will be invited to Teleggram group
It is not over.
Insurers have been issued with Intent to Claim.
Is what is needed here.
Armistice come in through the backdoor ( acquire Oxford Finance) put together a recovery plan which the Adminstrators accept and get approval from Shareholders. Armistice ( American Hedge Fund) then decide their plan will not work. Seems Armistice did not undertake due diligence before putting forward the plan so are either totally incompetent or extremely devious.
Now Peyton and Stephenson have resigned, leaving 2 Americans and 2 Germans on the board.
Smell a Rat and enormouse Rat?
A Good Journalist should expose exactly what is/has gone on at 4D
Hi, there are some really switched on folks on this board who have followed this company for years. If you haven’t already please consider joining the action group as outlined by RightOn (thank you) many months ago. Your knowledge could be absolutely crucial as the group moves forward.
Here's the link below to Telegram for the shareholder action group. You will need to be subscribed to Telegram before you can join, then copy and go with the link below and you should get in. Let me know here of any problems. In order to have this pass the rules, I have added 5 spaces to the address, which you will have to delete.
Htt ps://t . me / +1ngv2N1p4qZhZDlk
no not me yet. sent my email on 14th march 23.
same no reply to me either. I sent my email to him on 14th March 23.
Those are good points Porky.
What I have learned going forward is that AIM biotech companies are very high risk - the odds of getting something to work is very low and they burn through cash (by way of dilution) rapidly.
The governance of AIM companies is also poor as we don’t truly know what is happening.
My lesson from all of this is that AIM biotech is not worth the investment, or at the very least you need to be prepared to loose everything.
I was also invested in Reneuron a while back, an AIM pharma company. Luckily for me I bailed out of it before the sp collapsed from around 60p (my investment) to currently 10p.
Anybody new reading this - just be careful with any AIM company.
What this whole debacle regarding 4D tells us is that realistically the valuations that the brokers assign to these AIM plays often bares no resemblance what so ever to realistic company value. Never has it been truer that something is only worth what someone will pay for it.
Parking to one side the atrocious management, cash burn, ten years of development funded by shareholders and wasted cash etc etc etc in terms of actual drug pipeline assets, this business had 14 drug lines, 9 of which at significant advanced stages towards licensing and commercialisation, One of which had recently secured FDA clearance and was on the cusp of a licensing deal. These drug lines were backed and partnered by some of the biggest names in the industry.
When they raised £18m at £1.10 SP investors were being told investing in these drug lines could result in possible cures and help for some of life’s most atrocious illnesses. One drug line alone could be worth £100m plus in licensing. Yet the stark reality is totally different.
The Interpath report on page 4 tells us that 50 large and medium Biotech companies were approached, remember that Merck were even a partner to a drug supporting their Keytruda drug doing $22 billion sales per year, there were 19 financial biotech players and despite some initial interest NONE came through with final offers. Not one. Nobody wanted to bid for ANY of the IP.
We now know that a two bit small Korean biotech has acquired all the rich IP assets for a token fee yet by my very rough calculation there has been over the years north of something like 100m of investors capital to get these drugs to the current stages.
There is no answer to this really and there will be a heck of lot of investors giving fledgling biotech investments a wide birth knowing that not only are the chances of success limited in most cases but even when the outlook is strong, big biotech are no longer paying decent upfront licensing fees, they only really want to pay after everything approved just before commercialisation. If the biotech goes bust in the meantime, they can pick up the IP for a token fee if they want it.
At this rate biotech investment will continue to dry up, perhaps some extra tax breaks or something could help but certainly MMs should be materially reducing placing valuations that’s for sure. Often they are miles apart from what that IP is worth on the open market. The outcome here certainly endorses that point.
Common courtesy and decency tells me the Administrators, who have been payed £4m, should at least inform exactly how assets are/have been sold. I guess they will say shares have been cancelled and therefore no need to inform. However the assets, both tangible and intangible, are under someone's control. Should the Regulator be involved???
Disgusting ?? how can they get away with it
Once again, why have Interpath not announced this and notified Shareholders ?
Financial crime story at it's best!